Arrowhead Pharmaceuticals (ARWR) Stock Statistics & Valuation Metrics

Arrowhead Pharmaceuticals has a market cap or net worth of $8.92B. The enterprise value is $9.13B.

Arrowhead Pharmaceuticals has 140,032,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arrowhead Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is 4.65%.

The current PE Ratio of Arrowhead Pharmaceuticals is 41.9. Arrowhead Pharmaceuticals’s PEG ratio is 28.35.

In the last 12 months, Arrowhead Pharmaceuticals had revenue of 829.45M and earned -1.63M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was 339.31M and capital expenditures -17.30M, giving a free cash flow of 322.01M billion.

Arrowhead Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Arrowhead Pharmaceuticals upcoming earnings date is May 7, 2026, After Close (Confirmed).

Arrowhead Pharmaceuticals as a current ratio of 4.86, with Debt / Equity ratio of 55.02%

In the past 12 months, Arrowhead Pharmaceuticals has paid 21.42M in taxes.

Arrowhead Pharmaceuticals EV to EBITDA ratio is 28.84, with an EV/FCF ratio of 30.30.

Arrowhead Pharmaceuticals has $916.61M in cash and marketable securities with $312.77M in debt, giving a net cash position of $603.84M billion.

Gross margin is 99.43%, with operating margin of 11.86%, and net profit margin of -0.20%.

The average price target for Arrowhead Pharmaceuticals is $82.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy